Erlotinib Attenuates Homologous Recombinational Repair of Chromosomal Breaks in Human Breast Cancer Cells

Liping Li,1 Hong Wang,1 Eddy S. Yang,1 Carlos L. Arteaga,2,3,4 and Fen Xia1,3,4

Departments of 1Radiation Oncology, 2Medicine, and 3Cancer Biology and 4Breast Cancer Research Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee

Abstract

The epidermal growth factor receptor (EGFR) family has been implicated in several cancers, including breast, and its members have become the target of novel cancer therapies. In this report, we show a novel link between erlotinib, a potent EGFR inhibitor, DNA damage, and homology-directed recombinational repair (HDR) in human breast cancer cells. Erlotinib suppresses HDR. This is not secondary to erlotinib-mediated changes in cell cycle and is associated with increased γ-H2AX foci, which is an in situ marker of chromosomal double-strand breaks. Both Rad51 and BRCA1 are essential components of the HDR machinery. Consistent with decreased HDR in erlotinib-treated cells, erlotinib also attenuates DNA damage-induced Rad51 foci and results in cytoplasmic retention of BRCA1. As BRCA1 is a shuttling protein and its nuclear function of promoting HDR is controlled by its subcellular localization, we further show that targeted translocation of BRCA1 to the cytoplasm enhances erlotinib sensitivity. These findings suggest a novel mechanism of action of erlotinib through its effects on the BRCA1/HDR pathway. Furthermore, BRCA1/HDR status may be an innovative avenue to enhance the sensitivity of cancer cells to erlotinib. [Cancer Res 2008;68(22):9141–6]

Introduction

The epidermal growth factor receptor (EGFR) family plays an essential role in modulating proliferation, differentiation, and survival and has become a heavily targeted novel cancer therapeutic strategy (1). Aberrant expression and dysregulation of any EGFR can be found in several cancers, including lung, pancreas, head and neck, brain, and breast (1). In approximately 20% to 30% of breast cancers, overexpression of HER2/ErbB2 is seen and portends a more aggressive phenotype and poorer prognosis (1). However, with the development of molecular targeted therapies against HER2, such as trastuzumab (Herceptin), improved outcomes are being achieved. This success has initiated the pursuit of other compounds that can suppress HER2 activity. In particular, drugs that inhibit EGFR subtype HER1 are active against HER2 (2, 3). One such drug is erlotinib (Tarceva), an orally bioavailable small molecular weight inhibitor of HER1.

Erlotinib treatment results in blockade of multiple signal transduction pathways involved in cell proliferation and survival. In particular, erlotinib has been shown to inhibit growth and cause cells to accumulate in the G1 phase with a concomitant decrease in S phase of the cell cycle. Interestingly, erlotinib also decreases radiation-induced Rad51 expression and enhances radiation-induced apoptosis, suggesting a potential role of erlotinib in altering the DNA damage response (4). Similarly, gefitinib, a selective EGFR tyrosine kinase inhibitor, has been reported to elicit radiosensitization by suppressing cellular capacity to repair radiation-induced DNA damage (5). Furthermore, blockade of EGFR signaling with a monoclonal antibody (mAb) to the EGFR can inhibit radiation-induced activation of DNA-dependent protein kinase (DNA-PK) and increase radiosensitivity of treated cells (6). These studies thus support a role of EGFR in the DNA damage response.

The DNA damage response is commonly triggered on generation of DNA double-strand breaks (DSB), which can be repaired via two principal pathways: homology-directed recombinational repair (HDR) and nonhomologous end joining (NHEJ); refs. 7, 8). NHEJ, which occurs in all phases of the cell cycle, is an error-prone process that rejoins the ends of DSB with no or few homology. In contrast, HDR predominantly takes place in S phase of the cell cycle and is a high-fidelity process that requires an intact homologous DNA sequence as the template. Multiple proteins, including the Rad51 recombinase and BRCA1, are involved in this intricate process. Rad51 catalyzes the DNA strand invasion and exchange reaction in HDR, whereas BRCA1 promotes HDR through mechanisms involving chromatin remodeling and controlling the function of several other HDR proteins through protein-protein interactions (7). Recent studies also show that the function of BRCA1 in DNA repair is regulated by its nuclear shuttling (9).

In this study, we investigated the effects of erlotinib on DNA damage and repair in human breast cancer cells. We show for the first time that erlotinib treatment itself results in decreased HDR events and increased chromosomal DSBs in human breast cancer cells. Consistent with decreased HDR, DNA damage-induced Rad51 foci are attenuated by erlotinib. As the function of BRCA1 in promoting HDR-mediated DSB repair is dependent on its nuclear localization, we also find that erlotinib reduces nuclear BRCA1 levels with a concomitant sequestration of BRCA1 to the cytosol. It is worth to note that these effects are not indirect events due to erlotinib-mediated cell cycle changes. Furthermore, we show that targeted translocation of BRCA1 to the cytoplasm in breast cancer cells enhances erlotinib-mediated cytotoxicity. Taken together, these novel findings suggest that, in addition to its effects on cell cycle, the action of erlotinib may also involve BRCA1 and the HDR machinery.

Note: Supplementary data for this article are available at Cancer Research Online (http://cancerres.aacrjournals.org/).

H. Wang and E.S. Yang contributed equally to this work.

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or NIH.

Requests for reprints: Fen Xia, Department of Radiation Oncology, Vanderbilt University Medical Center, The Vanderbilt Clinic, 1301 22nd Avenue South, B-902 TVC, Nashville, TN 37232-5671. Phone: 615-322-2555; Fax: 615-343-6589; E-mail: fen.xia@vanderbilt.edu.

©2008 American Association for Cancer Research.

doi:10.1158/0008-5472.CAN-08-1127


Downloaded from cancerres.aacrjournals.org on April 14, 2017. © 2008 American Association for Cancer Research.
Materials and Methods

Cell culture. Previously established MCF7DRGFP cells (9), which were kindly provided by Dr. Simon Powell (Washington University School of Medicine, St. Louis, MO), were maintained as previously described. MCF7DRGFP cells carry a chromosomally integrated HDR substrate. All transfections were performed using FuGene6 according to the manufacturer’s recommendations (Roche).

Immunofluorescence. MCF7DRGFP cells were cultured and mounted onto sterile glass slides. Cells were then treated with DMSO vehicle, 1 μmol/L erlotinib, 4 Gy radiation, or 1 μmol/L erlotinib followed by 4 Gy radiation. Following the treatment period, immunohistochemistry was performed as previously described (9). Primary antibodies include 200 μg/μL mouse anti-phospho-γ-H2AX antibody (Upstate), rabbit anti-Rad51 antibody (1:500; Calbiochem), or mouse anti-BRCA1 (1:100; Ab-1; mouse mAb MS110; Calbiochem). Secondary antibodies include anti-mouse Alexa Fluor 488–conjugated antibody (1:1,000; Molecular Probes) or anti-rabbit Alexa Fluor 594–conjugated antibody (1:1,000; Molecular Probes). Staining patterns were visualized via fluorescence microscopy (Carl Zeiss). A total of 50 cells were counted per field, and a total of 10 fields were assessed. For foci analysis, cells with >10 foci were counted. For BRCA1 localization, cells were assessed as having nuclear staining only, cytoplasmic staining only, or both nuclear/cytoplasmic staining (8).

Chromosomal HDR analysis. HDR was assessed as previously described (10). Briefly, MCF7DRGFP cells were treated with either DMSO vehicle, 1 μmol/L erlotinib, or 6 μmol/L erlotinib for 16 h. Two days after transfection with I-SceI expression plasmid or empty vector (total exposure to erlotinib for 64 h), cells were subjected to two-color fluorescence analysis, which revealed the percentage of green fluorescent cells relative to the total cell number. For each analysis, 100,000 cells were processed. All transfections were performed using FuGene6.

Cell cycle analysis. MCF7DRGFP cells were treated with DMSO vehicle, 1 μmol/L erlotinib, or 6 μmol/L erlotinib or serum starved for the indicated times. Following the treatment period, cell cycle distribution was determined using standard ethanol fixation and propidium iodide staining followed by flow cytometry as previously described (10).

Clonogenic survival assay. The colony-forming ability was evaluated in MCF7DRGFP cells transiently expressing either vector control or a peptide containing truncated BRCA1 (trBRCA1), which has been shown to effectively shift BRCA1 to the cytoplasm (11). Briefly, cells were transfected with either vector control or trBRCA1. Twenty-four hours after transfection, cells were subjected to the treatment with either DMSO or the indicated dose of erlotinib. Colonies were stained and counted as positive if >50 cells were seen. Survival fraction was calculated as follows: (number of colonies for erlotinib/number of cells plated)/(number of colonies for corresponding control/number of cells plated).

Statistical analysis. The data were analyzed via either t-test (HDR analysis) or ANOVA followed by a Bonferroni post test (remaining data) using GraphPad Prism version 4.02 for Windows (GraphPad Software).

Results

Erlotinib increases γ-H2AX foci. The downstream actions of erlotinib are mediated by inhibition of the mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt pathways. As these effects can result in altered expression and localization of proteins involved in the DNA damage response and enhance ionizing radiation–induced cytotoxicity (4–6, 12, 13), we investigated whether erlotinib alone can increase nuclear γ-H2AX foci, markers of DNA DSBs in the breast cancer cell line MCF7DRGFP derived from the well-established MCF7 cell line and carries a single copy of a chromosomally integrated HDR substrate (10).

As seen in Fig. 1, treatment of MCF7DRGFP cells for 16 hours with 1 μmol/L erlotinib leads to a 5-fold increase (15% versus 3%; P < 0.001) in γ-H2AX foci compared with vehicle-treated cells. Foci can also be seen in 40% of cells 30 minutes following exposure to radiation, which is a potent inducer of DNA DSB and γ-H2AX foci. The combination of erlotinib and radiation enhances γ-H2AX foci compared with radiation alone (48% versus 40%; P < 0.01). Consistent with previous reports (4–6), these results further substantiate a link between EGFR inhibition and the DNA damage response.

Erlotinib decreases HDR. As a result of increased DNA DSB, cells trigger DNA damage checkpoints and activate the DNA repair machinery (9, 14). Because erlotinib increases γ-H2AX foci, which are indicative of DNA DSBs, and has been previously shown to decrease the expression of the HDR protein Rad51 after radiation, we investigated the effects of erlotinib on cellular capacity to repair DSBs via HDR. In these experiments, site-specific chromosomal DSBs were induced in MCF7DRGFP cells by the transient expression of the I-SceI endonuclease. Only HDR using the homology between

Figure 1. Erlotinib and radiation increase γ-H2AX foci in human breast cancer cells. MCF7DRGFP cells were treated with DMSO vehicle, 1 μmol/L erlotinib for 16 h, 4 Gy radiation alone, or 1 μmol/L erlotinib for 16 h followed by 4 Gy radiation. Following the erlotinib treatment period or 30 min after radiation, cells were assessed for γ-H2AX foci. Shown is the % of foci-containing cells with >10 foci. Inset, a representative staining of increased γ-H2AX foci (green) in erlotinib-treated cells (bottom) compared with untreated cells (top). Cell nuclei were also stained with 4,6-diamidino-2-phenylindole (DAPI; blue). Merge of the two stains is also shown. *, P < 0.01; **, P < 0.001.
the two mutated founder green fluorescent protein (GFP) repeats can restore GFP function. Expression of GFP in these cells was then quantified using flow cytometry. As shown in Fig. 2A, 1 μmol/L erlotinib significantly decreases the percentage of GFP-positive cells compared with control cells (0.63% versus 0.3%; \( P < 0.001 \)), resulting in a 2-fold decrease in HDR efficiency. This concentration of erlotinib has been shown to induce cytotoxic effects in breast cancer cells and correspond to clinically relevant doses (15). In addition, these HDR effects are not due to differences in cell viability or transfection efficiency, which are included as controls in all HDR assays.

It is known that one of the mechanisms for erlotinib-mediated cytotoxicity is via induced accumulation of cells at the G1 phase of cell cycle with a concomitant decrease of cells in S and G2-M phases. Given that HDR predominantly takes place in S phase when DNA replication occurs, we next examined whether our observed decrease in HDR by erlotinib is an indirect result of erlotinib-mediated changes in cell cycle, such as a dramatic reduction of cells in S-phase or accumulation in G1 phase. When analyzed at 24, 48, and 72 hours following 1 μmol/L erlotinib treatment, there is no significant decrease of cells in S phase or accumulation of cells in G1 phase (Fig. 2B) to account for the erlotinib-mediated 2-fold decrease in HDR. However, in agreement with previous reports, 6 μmol/L erlotinib robustly induces a significant G1 accumulation similar to that of serum starvation as early as 24 hours (46% cells in G1; Supplementary Fig. S1A). These observations suggest that the effects of erlotinib may involve the down-regulation of HDR and are not secondary to erlotinib-mediated cell cycle effects.

Erlotinib attenuates radiation-induced Rad51 foci and sequesters BRCA1 in the cytoplasm. To further explore erlotinib-mediated decrease in HDR, we investigated Rad51 foci, a well-characterized \textit{in vivo} functional marker of HDR. MCF7\textsuperscript{DRGFP} cells were exposed to 1 μmol/L erlotinib for 16 hours, and Rad51 foci were examined. As seen in Fig. 3A, erlotinib alone does not significantly affect Rad51 foci (11% versus 12%). However, the sensitivity of this assay may not be sufficient to detect erlotinib-mediated effects on Rad51 foci. To amplify this DNA damage response as well as to obtain a reference control, radiation was used, which results in robust induction of Rad51 foci (Fig. 3A). Consistent with the decreased HDR seen with erlotinib, radiation-induced Rad51 foci are significantly attenuated by erlotinib (51% versus 35% of cells; \( P < 0.001 \)). This agrees with previously observed reduction of radiation-induced Rad51 expression by erlotinib in human lung and head and neck cancers (4).

BRCA1 plays a critical role in the DNA damage response pathway and promotes error-free HDR. Recent studies show that BRCA1 is a shuttling protein, which is retained in the nucleus during S phase and accumulates in the cytosol during mitosis (9). In response to radiation-induced DNA damage, nuclear export of BRCA1 to the cytoplasm is observed in a p53-dependent manner (9). Specifically, the functions of BRCA1 in promoting HDR are dictated by its nuclear localization (9, 16). We thus sought to determine whether the effects of erlotinib on HDR inhibition involve changes in BRCA1 localization, which controls its nuclear function of repair. MCF7\textsuperscript{DRGFP} cells with functional p53 exhibit
a robust radiation-induced BRCA1 cytoplasmic translocation (Fig. 3B), which is consistent with previous reports (9). Interestingly, after 16 hours of 1 μmol/L erlotinib treatment, a significant cytoplasmic shift of BRCA1 is observed in MCF7DRGFP cells when compared with untreated cells (25% versus 10%; P < 0.001; Fig. 3B). It is worth to note that there is no cell cycle effect observed from erlotinib at this time and dose (Fig. 2B). With the combination of erlotinib and radiation, this effect is further enhanced (51% versus 75% of cells; P < 0.001 versus radiation alone). These findings suggest a potential link between erlotinib-mediated effects on BRCA1 localization and down-regulation of HDR.

**Nuclear repair function of BRCA1 is critical for sensitivity to erlotinib.** Given that the critical function of nuclear BRCA1 involves promoting HDR-mediated repair of DSB, we next assessed the role of BRCA1 in erlotinib-mediated cytotoxic effects. As HDR depends on BRCA1 nuclear localization, we reasoned that depletion of nuclear BRCA1 would inhibit HDR and thus augment the cytotoxic actions of erlotinib through HDR suppression. To achieve this, we used a peptide containing trBRCA1, which contains the BRCA1 nuclear export sequence and BARD1 binding domain and has been shown to effectively shift BRCA1 to the cytoplasm (11, 16). Ectopic expression of trBRCA1 in MCF7 cells results in a 2-fold reduction (40% versus 20%) in nuclear BRCA1 (Fig. 4A) and 10-fold inhibition (0.33% versus 0.03%) of HDR activity (Fig. 4B).

Having established that trBRCA1 can deplete nuclear BRCA1 and inhibit HDR capacity, we next assessed the effect of altering BRCA1 localization (and hence HDR) on erlotinib-mediated cytotoxicity. trBRCA1 was transiently expressed in MCF7 cells. Twenty-four hours after transfection, cells were treated with erlotinib for 72 hours, and clonogenic survival following erlotinib treatment was assessed. As shown in Fig. 4C, 1 μmol/L erlotinib induces a cytotoxic effect. Furthermore, targeted translocation of BRCA1 to the cytosol enhances this cytotoxic response of MCF7DRGFP breast cancer cells to erlotinib. We also examined the cytotoxic effect of a higher dose (6 μmol/L) of erlotinib, which induces more than 4-fold decrease of HDR (Supplementary Fig. S1B) and 2-fold increased accumulation of cells in G1 phase (Supplementary Fig. S1A). As seen in Fig. 4C, the survival fraction of cells at this concentration is reduced compared with 1 μmol/L, likely due to the combined effects of erlotinib-mediated cell cycle redistribution and suppression of HDR at 6 μmol/L. Interestingly, an enhanced cytotoxicity by erlotinib continues to be observed following BRCA1 translocation to the cytosol (and hence reduced HDR) by trBRCA1. Together, our findings in this study suggest a potential role for the BRCA1-HDR pathway in the cytotoxic effects of erlotinib beyond its cell cycle effects.

**Discussion**

In this study, we show that erlotinib treatment of human breast cancer cells results in suppression of HDR and increased basal levels of γH2AX foci, which are indicative of accumulation of DNA DSBs. Inhibition of HDR is also associated with sequestration of BRCA1 to the cytoplasm and attenuation of DNA damage-induced Rad51 foci but is not an indirect result of erlotinib-mediated cell cycle effects. Furthermore, disruption of the repair function by targeted translocation of BRCA1 to the cytoplasm enhances erlotinib-mediated cytotoxicity. These findings suggest a novel link between erlotinib-mediated cytotoxicity, DNA damage, and the HDR machinery in human breast cancer cells.

HDR is a complex process that is intricately tied to the cell cycle. We and others have previously reported a dependence of HDR and HDR protein subcellular localization on cell cycle distribution (9). Because erlotinib has been reported to induce G1 accumulation (4),...
it is important that the effect on HDR by erlotinib is not secondary to erlotinib-mediated changes in cell cycle distribution. As shown in Fig. 2B, low doses (1 μmol/L) of erlotinib do not result in significant changes in cell cycle distribution, specifically no S-phase reduction, to account for a 2-fold reduction in HDR capacity. In addition, higher doses of erlotinib (6 μmol/L) robustly induce G2 accumulation at similar magnitudes as serum starvation as early as 24 hours following treatment. However, a further enhanced cytotoxicity can still be observed by manipulation of HDR through

changing BRCA1 localization. Thus, the erlotinib-mediated reduction of HDR seems to be independent of, and in addition to, the cell cycle effects of erlotinib.

Recent reports suggest that sensitivity to erlotinib is dependent on regulation of the phosphatidylinositol 3-kinase/Akt pathway, which can alter the DNA damage response (17). Downstream Akt targets, such as the FoxO subfamily of forkhead transcription factors and MDM2, have been shown to stimulate the DNA damage and repair pathways (12, 13). In addition, radiation-induced Rad51 expression is reduced following erlotinib exposure in human lung and head and neck cancers (4).

Our results indicate that the underlying mechanisms by which erlotinib down-regulates HDR may involve BRCA1. Recent studies have shown that BRCA1 function is dictated by its subcellular localization (9, 16). In particular, BRCA1-mediated HDR occurs in the nucleus (16). We find that after 16 hours of erlotinib treatment, a time at which no significant changes in cell cycle are observed, nuclear BRCA1 levels are reduced. This suggests that erlotinib-mediated suppression of HDR may occur at least in part via sequestration of BRCA1 in the cytoplasm. Consistent with this notion is that forced shift of BRCA1 to the cytoplasm enhances erlotinib-mediated cytotoxicity in BRCA1-expressing cells. Alternatively, erlotinib may cause DSBs, which could induce BRCA1 cytoplasmic redistribution similar to our previous report of radiation-induced BRCA1 nuclear export (9). This change in BRCA1 localization would then alter HDR capacity such that erlotinib-induced DSBs cannot be repaired and thus lead to cytotoxicity.

Inhibition of EGFR signaling has also been implicated in radiation-induced activation of the DNA damage response. Radiation-induced nuclear import of the EGFR has been associated with induction of DNA-PK–dependent repair of DSBs through NHEJ, and blockade of EGFR with a mAb prevents this activation leading to radiosensitization (6). It is possible that erlotinib may also have effects on the NHEJ DNA repair pathway. Our preliminary studies do not show a significant difference in erlotinib-mediated activation of DNA-PK foci (data not shown). However, further in-depth investigation is warranted to determine if erlotinib affects NHEJ.

In summary, our findings indicate that the cytotoxic effects of erlotinib occur, in part, via down-regulation of HDR and sequestration of BRCA1 to the cytoplasm away from its role in HDR in the nucleus. This is not secondary to erlotinib-mediated cell cycle effects. Furthermore, targeting of BRCA1 away from the nucleus enhances erlotinib-mediated cytotoxicity. These results suggest the potential use of BRCA1/HDR status as a molecular marker to predict patient response to erlotinib. Additionally, the BRCA1/HDR pathway may be a potential target to sensitize cancer cells to erlotinib.

**Disclosure of Potential Conflicts of Interest**

No potential conflicts of interest were disclosed.

**Acknowledgments**

Received 3/31/2008; revised 9/17/2008; accepted 9/26/2008.

Grant support: NIH grant R01 CA118158-02 (F. Xia), Radiological Society of North America grant RB0725 (E.S. Yang), and National Cancer Institute grant P50CA095103.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Dr. Simon Powell for generously providing MCF7-DRGFP cells.
References

Erlotinib Attenuates Homologous Recombinational Repair of Chromosomal Breaks in Human Breast Cancer Cells

Liping Li, Hong Wang, Eddy S. Yang, et al.


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/68/22/9141

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2008/11/07/68.22.9141.DC1

Cited articles
This article cites 17 articles, 10 of which you can access for free at:
http://cancerres.aacrjournals.org/content/68/22/9141.full.html#ref-list-1

Citing articles
This article has been cited by 19 HighWire-hosted articles. Access the articles at:
/content/68/22/9141.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.